DiaSorin S.p.A. - news published 84 - readings 4.868

BACK
DiaSorin S.p.A.

DiaSorin S.p.A.

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark

D IASORIN LAUNCHES THE S IMPLEXA ™ C . AURIS DIRECT ASSAY ON THE LIAISON ® MDX INSTRUMENT IN ALL COUNTRIES ACCEPTING THE CE M ARK T HE S IMPLEXA ™ C . AURIS DIRECT ASSAY : AIDS IN THE PREVENTION AND CONTROL OF C ANDIDA AURIS , A RAPIDLY EMERGING MULTIDRUG - RESISTANT FUNGAL PATHOGEN COMMONLY FOUND IN HEALTHCARE SETTINGS ; IS A REAL - TIME POLYMERASE CHAIN REACTION ASSAY R ...

Continue reading
18.03.2025
DiaSorin S.p.A.

DiaSorin S.p.A.

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share

T HE B OARD OF D IRECTORS OF D IASORIN S P A APPROVES FY2024 R ESULTS WITH REVENUES AND NET PROFIT IN EXPANSION COMPARED TO P REVIOUS Y EAR ; P ROPOSED O RDINARY D IVIDEND OF € 1.20 PER SHARE R EVENUES : € 1,185 MILLION , +3% COMPARED TO 2023; +7% EX COVID AND AT CONSTANT EXCHANGE RATES (CER) A DJUSTED 1 EBITDA 2 : € 394 MILLION , +5% COMPARED TO 2023 , EQUAL TO 33% OF R ...

Continue reading
14.03.2025
DiaSorin S.p.A.

DiaSorin S.p.A.

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX®

D IASORIN A NNOUNCES 510( K ) S UBMISSION FOR LIAISON PLEX ® G RAM -P OSITIVE B LOOD C ULTURE A SSAY , TO COMPLETE THE B LOOD C ULTURE PORTFOLIO ON LIAISON PLEX ® Saluggia, Italy - November 11, 2024 - Diasorin (FTSE MIB: DIA) today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the LIAISON PLEX ® Gram-Positive B ...

Continue reading
11.11.2024
DiaSorin S.p.A.

DiaSorin S.p.A.

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance

D IASORIN REPORTS ANOTHER QUARTER WITH R EVENUES AND P ROFITABILITY IN EXPANSION , RAISING THE F ULL -Y EAR 2024 R EVENUE G UIDANCE R EVENUES : € 876 MILLION , +4% " AS REPORTED " COMPARED TO S EPTEMBER 2023; +7% E X C OVID (+8% AT CONSTANT PERIMETER OF CONSOLIDATION 1 ) A DJUSTED 2 EBITDA 3 : € 292 MILLION , +6% AT CONSTANT EXCHANGE RATES COMPARED TO 9M 2023 , E ...

Continue reading
05.11.2024
DiaSorin S.p.A.

DiaSorin S.p.A.

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay

LIAISON PLEX ® D IASORIN A NNOUNCES 510( K ) S UBMISSION FOR LIAISON PLEX ® G RAM -N EGATIVE B LOOD C ULTURE A SSAY , THE SECOND PANEL FOR THE DIAGNOSIS OF BLOODSTREAM INFECTIONS ON THE Saluggia, Italy - September 27, 2024 - Diasorin (FTSE MIB: DIA) today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the LIAISON ...

Continue reading
27.09.2024
DiaSorin S.p.A.

DiaSorin S.p.A.

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark

D IASORIN LAUNCHES THE LIAISON ® S TREPTOCOCCUS PNEUMONIAE A G ASSAY IN ALL COUNTRIES ACCEPTING THE CE M ARK FOR THE DIAGNOSIS OF P NEUMOCOCCAL PNEUMONIA T HE LIAISON ® S. PNEUMONIAE A G ASSAY : IS THE FIRST SOLUTION THAT COMES TO MARKET ALLOWING HIGH - THROUGHPUT QUALITATIVE DETECTION OF S. PNEUMONIAE ANTIGEN IN URINE SPECIMENS OF ADULT PATIENTS ; DIAGNOSES AND DISCRIMINATE ...

Continue reading
09.09.2024
DiaSorin S.p.A.

DiaSorin S.p.A.

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer DiaSorin S.p.A. published this content on 29 July 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 29 July 2024 14:01:21 UTC .

Continue reading
29.07.2024
DiaSorin S.p.A.

DiaSorin S.p.A.

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument

D IASORIN RECEIVES FDA DE - NOVO GRANT FOR THE S IMPLEXA ® C. AURIS D IRECT ASSAY ON THE LIAISON ® MDX INSTRUMENT SIMPLEXA ® C. AURIS D IRECT : IS A FIRST OF A KIND FDA DE - NOVO GRANTED ASSAY TO AID IN THE PREVENTION AND CONTROL OF C ANDIDA AURIS , A RAPIDLY EMERGING MULTI DRUG - RESISTANT FUNGAL PATHOGEN COMMONLY FOUND IN HEALTHCARE SETTINGS ; IS A REAL - TIME POLYMERASE ...

Continue reading
16.07.2024
DiaSorin S.p.A.

DiaSorin S.p.A.

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX®

D IASORIN R ECEIVES FDA 510( K ) C LEARANCE FOR THE LIAISON PLEX ® B LOOD C ULTURE Y EAST A SSAY ON THE NEW MULTIPLEXING LIAISON PLEX ® T HE LIAISON PLEX ® Y EAST B LOOD C ULTURE A SSAY : IS THE SECOND MULTIPLEXING MOLECULAR DIAGNOSTIC PANEL ON THE LIAISON PLEX ® TO BE CLEARED BY THE U.S. FDA, AFTER THE R ESPIRATORY F LEX A SSAY , WHICH RECEIVED CLEARANCE IN M ARCH 2024 IS ...

Continue reading
05.06.2024
DiaSorin S.p.A.

DiaSorin S.p.A.

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2

D IASORIN RECEIVES FDA 510( K ) CLEARANCE FOR THE UPDATED SYNDROMIC PANEL N X TAG ® R ESPIRATORY P ATHOGEN P ANEL V 2 N X T AG ® R ESPIRATORY P ATHOGEN P ANEL (RPP) V 2 IS A MOLECULAR MULTIPLEX PANEL THAT DETECTS 21 DIFFERENT PATHOGENS ( BACTERIA , VIRUSES ) T HE RPP V 2 PANEL IS NOW AVAILABLE IN THE U.S. ON THE MAGPIX ® SYSTEM T HE NEW UPDATED PANEL ADDS TO D IASORIN ' S M ...

Continue reading
16.05.2024
DiaSorin S.p.A.

DiaSorin S.p.A.

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance

Q1 R EVENUES AND A DJUSTED E BITDA IN LINE WITH THE HIGH RANGE OF THE FY'24 GUIDANCE R EVENUES : € 289 MILLION ( IN LINE WITH 2023 REPORTED REVENUES ; +7% AT CER, EXCLUDING C OVID AND AT CONSTANT PERIMETER 1 ) A DJUSTED 2 E BITDA 3 : € 97 MILLION , EQUAL TO 34% OF G ROUP REVENUES Saluggia (Italy), May 10, 2024 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), ex ...

Continue reading
10.05.2024